XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
| Autor: | Pietanza MC, Lynch TJ Jr, Lara PN Jr, Cho J, Yanagihara RH, Vrindavanam N, Chowhan NM, Gadgeel SM, Pennell NA, Funke R, Mitchell B, Wakelee HA, Miller VA |
|---|---|
| Zdroj: | Journal of Thoracic Oncology; 2012 Jan, Vol. 7 Issue 1, p219-226, 8p |
| Databáze: | Complementary Index |
| Externí odkaz: |
|